USFDAJul 1, 2026, 09:31 AM
NewcelX Completes Pre-IND Meeting with FDA for NCEL-101
AI Summary
NewcelX announced the successful completion of its Type B Pre-IND meeting with the U.S. FDA for its lead candidate, NCEL-101, for type 1 diabetes. The FDA provided constructive feedback and alignment on the company's development strategy, offering clarity on the regulatory pathway for a clinical trial. This represents a significant milestone toward clinical development of NCEL-101, which will be combined with Eledon Pharmaceuticals' tegoprubart.
Key Highlights
- Completed Type B Pre-IND meeting with U.S. FDA for NCEL-101.
- FDA provided constructive feedback and alignment on development strategy.
- Received clarity on regulatory pathway for clinical trial of NCEL-101.
- NCEL-101 to be combined with Eledon's anti-CD40L antibody, tegoprubart.
- FDA gave favorable feedback on CMC processes and preclinical program.
- NCEL-101 preclinical data: ~60% Beta cells, 99.98% endocrine lineage.
Price Impact
More from NCEL